Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lippman

Showing results (341-350 of 551) with videos related to

Pageof 56
Sort By:
Oncogene|April 17, 1997
Frequent inactivation of p16INK4a in oral premalignant lesionsV Papadimitrakopoulou, J Izzo, S M Lippman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2012
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemopreventionMichelle A T Hildebrandt, Scott M Lippman, Carol J Etzel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 25, 2001
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokersF R Khuri, J S Lee, S M Lippman, et al.
The New England Journal of Medicine|April 9, 2004
The influence of resection and aneuploidy on mortality in oral leukoplakiaJon Sudbø, Scott M Lippman, J Jack Lee, et al.
Cancer|April 3, 2001
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinomaD M Shin, F R Khuri, B S Glisson, et al.
Cancer Research|July 19, 2005
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived productsJeri Kim, Peiying Yang, Milind Suraokar, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
The New England Journal of Medicine|September 20, 1990
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neckW K Hong, S M Lippman, L M Itri, et al.
Gynecologic Oncology|January 15, 1999
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trialG R Weiss, P Y Liu, D S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neckB Brockstein, D J Haraf, K Stenson, et al.
Pageof 56

Showing results (341-350 of 551) with videos related to

Sort By:
Pageof 56
Oncogene|April 17, 1997
Frequent inactivation of p16INK4a in oral premalignant lesionsV Papadimitrakopoulou, J Izzo, S M Lippman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2012
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemopreventionMichelle A T Hildebrandt, Scott M Lippman, Carol J Etzel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 25, 2001
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokersF R Khuri, J S Lee, S M Lippman, et al.
The New England Journal of Medicine|April 9, 2004
The influence of resection and aneuploidy on mortality in oral leukoplakiaJon Sudbø, Scott M Lippman, J Jack Lee, et al.
Cancer|April 3, 2001
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinomaD M Shin, F R Khuri, B S Glisson, et al.
Cancer Research|July 19, 2005
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived productsJeri Kim, Peiying Yang, Milind Suraokar, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
The New England Journal of Medicine|September 20, 1990
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neckW K Hong, S M Lippman, L M Itri, et al.
Gynecologic Oncology|January 15, 1999
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trialG R Weiss, P Y Liu, D S Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neckB Brockstein, D J Haraf, K Stenson, et al.
Pageof 56